3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
15
Vitamin D Deficiency
13
Prostatic Neoplasms
13
Polycystic Ovary Syndrome
8
Neoplasms
7
Osteoporosis
4
Colorectal Neoplasms
4
Warts
3
Rectal Neoplasms
3
Ovarian Neoplasms
3
Myelodysplastic Syndromes
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Colonic Neoplasms
3
Brain Neoplasms
3
Male Urogenital Diseases
2
Leukemia
2
Cardiovascular Diseases
2
Adenomatous Polyps
2
Stroke
1
Spinal Cord Injuries
1
Skin Neoplasms
1
Seizures
1
Psoriasis
1
Prostate Adenocarcinoma
1
Premature Birth
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polyps
1
Pathologic Processes
1
Pain
1
Osteoarthritis
1
Interventions
Cyclophosphamide
85
Rituximab
80
Peripheral Blood Stem Cell Transplantation
60
fludarabine phosphate
58
Filgrastim
40
Mycophenolic Acid
37
Whole-Body Irradiation
35
Cyclosporine
35
Radiotherapy
33
Etoposide
33
Busulfan
33
Tacrolimus
31
Antilymphocyte Serum
28
Melphalan
26
Methotrexate
22
Prednisone
19
Bortezomib
19
Methylprednisolone
16
Cytarabine
16
Vincristine
15
Lenalidomide
15
Flow Cytometry
14
Cord Blood Stem Cell Transplantation
13
sargramostim
12
Doxorubicin
12
Bendamustine Hydrochloride
12
fludarabine
11
Dexamethasone
11
Carmustine
11
Carboplatin
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, B-Cell, Marginal Zone
×
Cholecalciferol
×
Clear all
NCT03078855
2024-09-04
ILyAD
University of Rochester
Phase 3
Completed
211 enrolled
13 charts